Latin America is facing a crisis in the diagnosis and treatment of cancer patients. Over the last two years, due to the direct result of pressure on local medical systems from COVID-19, an unknown number of patients have failed to receive diagnoses and treatments for various cancers. As a result of delayed diagnosis and, in turn, treatment, both mortality rates and treatment costs for later-stage diseases will increase, while patient quality-of-life and survival metrics will likely show decreases in the coming years. As governments face greater costs for treating a surge of later-stage patients, the regulatory environment will begin to shift. Clients in the healthcare space must prepare right now for the impending policy and regulatory evolution as medical systems in Latin America confront this crisis and fight to enhance patient outcomes.